These findings suggest a potential role for Lp(a)-targeting medications in managing AAA in combination with ApoB-lowering medications like statins, which are recommended to reduce the concomitant risk of MACE among individuals with prevalent AAA.47 Here, APOB is linked to triple-A syndrome.